Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local immunotherapy with monobenzone and imiquimod for cutaneous melanoma metastases
2010-022703-22Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monobenzone and imiquimod in cutaneous melanoma (CM) and melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical efficacy of monobenzone + imiquimod on cutaneous metastases. Started Sep 2010; status: active.
02
Drugs
monobenzoneimiquimod
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2010-022703-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022703-22.